Skip main navigation

Military Health System

Clear Your Browser Cache

This website has recently undergone changes. Users finding unexpected concerns may care to clear their browser's cache to ensure a seamless experience.

Skip subpage navigation

DOD P&T Committee: 2022 Meetings

Nov. 2-3, 2022

Uniform Formulary Request for Quote Information (Class Review)Opens to Formulary Request

  • UF BPA & UF ADP RFQ Documents Posted: July 15, 2022
  • Pre-Proposal Teleconference: Aug. 10, 2022 at 1:00pm CT
  • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
  • UF BPA & UF ADP Class Quotes Due: Sep. 16, 2022 at 12:00pm CT

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • ATOPY - ORAL JAK-I:
    • Cibinqo
    • Rinvoq
  • HEMATOLOGICAL AGENTS - RBC STIMULANTS-ERYTHROPOETIN:
    • Epogen
    • Procrit
    • Retacrit

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

  • Aspruzyo
  • Entadfi
  • Freestyle Libre 3
  • Hyftor
  • Omnipod G6 (Gen 5)
  • Ryaltris
  • Sotyktu
  • Tadliq
  • Tascenso ODT
  • Vivjoa
  • Xaciato
  • Zonisade
  • Zoryve

 

 


Aug. 3-4, 2022

Uniform Formulary Request for Quote Information (Class Review)Opens to Formulary Request

  • UF BPA & UF ADP RFQ Documents Posted: April 22, 2022
  • Pre-Proposal Teleconference: May 11, 2022
  • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
  • UF BPA & UF ADP Class Quotes Due: June 9, 2022

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • ANTIDEPRESSANTS AND NON-OPIOID PAIN SYNDROME AGENTS - GAMMA-AMINOBUTYRIC ACID ANALOGS:
    • Gralise
    • Horizant
  • ANTIDEPRESSANTS AND NON-OPIOID PAIN SYNDROME AGENTS - NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS:
    • Aplenzin
  • ANTIDEPRESSANTS AND NON-OPIOID PAIN SYNDROME AGENTS - SELECTIVE SEROTONIN REUPTAKE INHIBITORS:
    • Pexeva
    • Trintellix
    • Viibryd
  • ANTIDEPRESSANTS AND NON-OPIOID PAIN SYNDROME AGENTS - SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS:
    • Drizalma
    • Fetzima
    • Savella
  • OVERACTIVE BLADDER AGENTS - BETA-3 ADRENERGIC AGONISTS:
    • Gemtesa
    • Myrbetriq
    • Myrbetriq Granules

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

  • Adlarity
  • Camcevi
  • Camzyos
  • Epsolay
  • insulin glargine
  • Lyvispah
  • Mounjaro
  • Norliqva
  • Quviviq
  • Radicava ORS
  • Tlando
  • Verkazia
  • Vijoice
  • Voquezna Dual Pak
  • Voquezna Triple Pak
  • Vtama
  • Ztalmy


May 4-5, 2022

Uniform Formulary Request for Quote Information (Class Review)Opens to Formulary Request

  • UF BPA & UF ADP RFQ Documents Posted: Jan. 21, 2022
  • Pre-Proposal Teleconference: Feb. 2, 2022
  • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
  • UF BPA & UF ADP Class Quotes Due: March 18, 2022

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • DIABETES NON INSULIN– GLP-1 AGONISTS INJECTABLE:
    • Bydureon Bcise
    • Byetta
    • Ozempic
    • Trulicity
    • Victoza
  • MIGRAINE AGENTS – ORAL CGRP:
    • Nurtec ODT
    • Qulipta
    • Ubrelvy

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

  • Adbry
  • Cibinqo
  • Dartisla ODT
  • Fleqsuvy
  • Ibsrela
  • Pyrukynd
  • Recorlev
  • Releuko syr. & vial
  • Seglentis
  • Soaanz
  • Tarpeyo
  • Twyneo
  • Vonjo
  • Zimhi


Feb. 9-10, 2022

Uniform Formulary Request for Quote Information (Class Review)Opens to Formulary Request

  • UF BPA & UF ADP RFQ Documents Posted: Oct. 26, 2021

  • Pre-Proposal Teleconference: Nov. 10, 2021

  • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)

  • UF BPA & UF ADP Class Quotes Due: Dec. 15, 2021

Class Review Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • BINDERS‐CHELATORS‐ANTIDOTES‐OVERDOSE AGENTS - HYPOGLYCEMIA AGENTS:
    • Baqsimi
    • Gvoke Hypopen
    • Gvoke Pre-Filled Syringe
    • Zegalogue Autoinjector
    • Zegalogue Syringe
  • ONCOLOGICAL AGENTS – MULTIPLE:
    • Afinitor Disperz
    • Cabometyx
    • Cometriq
    • Copiktra
    • Fotivda
    • Gilotrif
    • Inlyta
    • Inrebic
    • Iressa
    • Jakafi
    • Lenvima
    • Lynparza
    • Nexavar
    • Proleukin
    • Rubraca
    • Tagrisso
    • Talzenna
    • Venclexta
    • Venclexta Starting Pack
    • Vizimpro
    • Votrient
    • Zejula
    • Zortress
    • Zydelig

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

  • Besremi
  • Dhivy
  • Elyxyb
  • Eprontia
  • Livmarli
  • Livtencity
  • Qulipta
  • Scemblix
  • Skytrofa
  • Tyrvaya
  • Voxzogo
  • Tosymra

 


    If the DOD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.


    Subject to Change Disclaimer

    The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.

    Last Updated: January 12, 2023
    Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on X Follow us on YouTube Sign up on GovDelivery